Pharmacological treatment of obesity in liver transplant candidates: initial experience

Česká verze

Authors: R. Lukáčik ¹ ; A. Němcová ² ; P. Taimr ¹ ; H. Gottfriedová ¹ ; Pavel Trunečka ¹ ; M. Haluzík ² ; Tomáš Hucl ¹ ; Irena Míková ¹
Authors place of work: Klinika hepatogastroenterologie, IKEM, Praha ¹; Centrum diabetologie, IKEM, Praha ²
Published in the journal: Gastroent Hepatol 2026; 80(4): 308-313
Category: Klinická a experimentální gastroenterologie: původní práce
doi: https://doi.org/10.48095/ccgh2026308

Summary

Introduction and aims: Obesity is an increasing clinical problem among liver transplant (LT) candidates and is associated with worse patient and graft survival and a higher risk of complications. Clinical experience with pharmacological treatment of obesity using incretin--based anti-obesity agents in LT candidates remains very limited. The aim of our study was to evaluate the effect of pharmacological treatment of obesity in 3 LT candidates on changes in body weight, liver function, liver disease-related complications, and treatment tolerance. Methods: This retrospective analysis included LT candidates with class III obesity in whom pharmacotherapy of obesity using incretin-based anti-obesity agents was initiated in 2025. Results: We evaluated the course of treatment for obesity in three female LT candidates (aged 54–55 years) with class III obesity (BMI 43.4–44.5 kg/m²) and liver cirrhosis (Child-Pugh B–C, MELD-Na 17–20). Patients were treated with semaglutide, liraglutide, or tirzepatide for 6–12 months. Treatment led to a reduction in total body weight (TBWL) of 20.2%, 7.5%, and 6.2%. The change in MELD-Na score during treatment was −2, −3, and +4. Two patients showed improvement in liver function, leading to postponement of waitlisting; the third patient was listed and underwent LT, with a complicated post-transplant course. Treatment was well tolerated in all patients with no serious adverse events. Conclusion: Pharmacological treatment of obesity with incretin-based anti-obesity agents is feasible in selected stable LT candidates; however, attention must be paid to the risk of sarcopenia. The benefits and safety of this treatment in LT candidates should be confirmed in a prospective randomized trial.

Keywords:

liver transplantation – obesity – incretin-based anti-obesity agents – semaglutide – liraglutide – tirzepatide – liver cirrhosis – sarcopenia

Zdroje

1. Younossi ZM, Golabi P, Paik JM et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77 (4): 1335–1347. doi: 10.1097/HEP.0000000000000004.

2. Younossi ZM, Stepanova M, Al Shabeeb R et al. The changing epidemiology of adult liver transplantation in the United States in 2013–2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun 2024; 8 (1): e0352. doi: 10.1097/HC9.0000000000000352.

3. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35 (1): 105–109. doi: 10.1053/ jhep.2002.30318.

4. Giorgakis E, Tedeschi M, Bonaccorsi-Riani Eet al. The effect of recipient body mass index and its extremes on survival and graft vascular and biliary complications after liver transplantation: a single center retrospective study. Ann Transplant 2017; 22 : 611–621. doi: 10.12659/aot.903475.

5. LaMattina JC, Foley DP, Fernandez LA et al. Complications associated with liver transplantation in the obese recipient. Clin Transplant 2012; 26 (6): 910–918. doi: 10.1111/j.1399-0012. 2012.01669.x.

6. Beckmann S, Drent G, Ruppar T et al. Body weight parameters are related to morbidity and mortality after liver transplantation: a systematic review and meta-analysis. Transplantation 2019; 103 (11): 2287–2303. doi: 10.1097/TP.0000000000002811.

7. European Association for the Study of the Liver. EASL Clinical practice guidelines on liver transplantation. J Hepatol 2024; 81 (6): 1040–1086. doi: 10.1016/j.jhep.2024.07.032.

8. European Association for the Study of the Liver. EASL Clinical practice guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70 (1): 172–193. doi: 10.1016/j.jhep.2018.06.024.

9. Newsome PN, Buchholtz K, Cusi K et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384 (12): 1113–1124. doi: 10.1056/NEJMoa2028395.

10. Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025; 392 (21): 2089–2099. doi: 10. 1056/NEJMoa2413258.

11. Loomba R, Hartman ML, Lawitz EJ et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024; 391 (4): 299–310. doi: 10.1056/NEJMoa2401943.

12. Wang L, Berger NA, Kaelber DC et al. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology 2024; 167 (4): 689–703. doi: 10.1053/j.gastro.2024.04.029.

13. Wester A, Shang Y, Toresson Grip E et al. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut 2024; 73 (5): 835–843. doi: 10.1136/gutjnl-2023-330962.

14. Celsa C, Pennisi G, Tulone A et al. Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. Gut 2025; 74 (5): 815–824. doi: 10.1136/gutjnl-2024-334591.

15. Gonzalez HC, Myers DT, Venkat D. Successful implementation of a multidisciplinary weight loss program including GLP1 receptor agonists for liver transplant candidates with high body mass index. Transplantation 2024; 108 (11): 2233–2237. doi: 10.1097/TP.0000000000005070.

16. Locatelli JC, Costa JG, Haynes A et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?. Diabetes Care 2024; 47 (10): 1718–1730. doi: 10.2337/dci23-0100.

17. Tandon P, Ney M, Irwin I et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012; 18 (10): 1209–1216. doi: 10.1002/lt.23495.

18. van Vugt JL, Levolger S, de Bruin RW et al. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant 2016; 16 (8): 2277–2292. doi: 10.1111/ajt.13732.

19. Lai JC, Sonnenday CJ, Tapper EB et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transplant 2019; 19 (7): 1896–1906. doi: 10.1111/ajt.15392.

20. Jensen L, Kupcova V, Arold G et al. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab 2018; 20 (4): 998–1005. doi: 10.1111/dom.13186.

21. Oprea AD, Ostapenko LJ, Sweitzer B et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) Multidisciplinary Consensus Statement. Br J Anaesth 2025; 135 (1): 48–78. doi: 10.1016/j.bja.2025.04.001.

22. Huang X, Wu M, Huang B et al. Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Front Med (Lausanne) 2025; 12 : 1509947. doi: 10.3389/fmed.2025.1509947.